Poster Spotlight 2: Molecular Evolution in Early and Late Stage Tumors
Session Details
The text of the abstracts will be posted on Monday, November 24.
Moderator
Charles M Perou, University of North Carolina at Chapel Hill, Chapel Hill, NC
Presentation numberPD2-01
Immunohistochemical Subtype Conversion After Neoadjuvant Chemotherapy and Its Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis
Marcelo Antonini, Hospital do Servidor Publico Estadual, Sao Paulo, SP, Brazil
Presentation numberPD2-02
Stability of Estrogen receptor (ER), Progesterone receptor (PR), and Human epidermal growth factor receptor 2 (HER2) in Residual Invasive Tumor after Neoadjuvant Therapy in Inflammatory Breast Cancer
Savitri Krishnamurthy, The University of Texas MD Anderson Cancer Center, Houston, TX
Presentation numberPD2-03
Basal-like residual disease after neoadjuvant chemotherapy is immunologically cold and associated with poor prognosis in triple negative breast cancer CALGB 40603 (Alliance)
Patrick Dominik Rädler, University of North Carolina at Chapel Hill, Chapel Hill, NC
Presentation numberPD2-04
Tumor Heterogeneity in the transATAC Breast Cancer Spatial Single Cell Atlas
Eugene F. Schuster, The Institute of Cancer Research, London, United Kingdom
Presentation numberPD2-05
Discussant: Neoadjuvant
Brian D Lehmann, Vanderbilt-Ingram Cancer Center, Nashville, TN
Presentation numberPD2-06
Molecular causes of subtype switching in primary and metastatic breast tumor pairs from the AURORA US Project
Anna R Michmerhuizen, University of North Carolina at Chapel Hill, Chapel Hill, NC
Presentation numberPD2-07
Multi-omics characteristics of ER+/HER2- breast cancer switching to metastatic non-luminal subtype: findings from the AURORA study (BIG14-01)
Matteo Benelli, University of Florence, Florence, Italy
Presentation numberPD2-08
Detecting subtype switching in metastatic breast cancer with circulating tumor DNA methylation profiling
Nida Pasha, Institute of Cancer Reasearch, London, United Kingdom
Presentation numberPD2-09
Convergent genomic evolution from early to lethal HR+/HER2- metastatic breast cancer
Nolan Priedigkeit, Dana-Farber Cancer Institute / Broad Institute, Boston, MA
Presentation numberPD2-10
Discussant: Metastatic
Maggie Chon U Cheang, Institute of Cancer Research, London, United Kingdom